{
  "nctrialId": "HC-1667",
  "title": "A Randomized Open-Label, Placebo-Controlled Multi-Center Study of ALZ-309 (beta-amyloid antibody) in Patients With Parkinson's Disease",
  "officialTitle": "A Randomized Open-Label, Placebo-Controlled Multi-Center Study of ALZ-309 (beta-amyloid antibody) in Patients With Parkinson's Disease",
  "sponsor": "Montreal Heart Institute",
  "indication": "Parkinson's Disease",
  "phase": "Phase 3",
  "fileName": "HC-1667.json",
  "fileSize": 481489,
  "date": "2024-09-07",
  "completionDate": "2028-08-18",
  "drugName": "ALZ-309 (beta-amyloid antibody)",
  "source": "Health Canada Clinical Trials Database",
  "studyType": "Interventional",
  "status": "Recruiting",
  "description": "This is a randomized open-label, placebo-controlled multi-center study designed to evaluate the efficacy and safety of ALZ-309 (beta-amyloid antibody) in patients with Parkinson's Disease. The study will enroll approximately 478 patients.",
  "eligibilityCriteria": "\nInclusion Criteria:\n- Adults aged 20-84 years\n- Confirmed diagnosis of Parkinson's Disease\n- ECOG performance status 0-1\n- Adequate organ function\n- Willing and able to provide informed consent\n\nExclusion Criteria:\n- Known hypersensitivity to study drug or excipients\n- Pregnant or breastfeeding women\n- Participation in another interventional study within 30 days\n- Significant cardiovascular disease within past 6 months\n- Active or chronic infection requiring systemic treatment"
}